{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:00:54Z","timestamp":1792267254417,"version":"4.4.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-024-01160-1","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T03:29:50Z","timestamp":1737689390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["PI3K\/AKT\/mTOR Targeting in Colorectal Cancer Radiotherapy: A Systematic Review"],"prefix":"10.1007","volume":"56","author":[{"given":"SN","family":"Mousavikia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Darvish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AA","family":"Firouzjaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MT Bahreyni","family":"Toossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Azimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"3","key":"1160_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA: Cancer J Clin"},{"issue":"9","key":"1160_CR2","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3390\/cancers13092025","volume":"13","author":"T Sawicki","year":"2021","unstructured":"Sawicki T, Ruszkowska M, Danielewicz A, Nied\u017awiedzka E, Ar\u0142ukowicz T, Przyby\u0142owicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers. 2021;13(9):2025. https:\/\/doi.org\/10.3390\/cancers13092025.","journal-title":"Cancers"},{"issue":"5","key":"1160_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.2173","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA: Cancer J Clin. 2022;72(5):409\u201336. https:\/\/doi.org\/10.3322\/caac.2173.","journal-title":"CA: Cancer J Clin"},{"issue":"34","key":"1160_CR4","doi-asserted-by":"publisher","first-page":"20681","DOI":"10.1073\/pnas.2003771117","volume":"117","author":"C Paterson","year":"2020","unstructured":"Paterson C, Clevers H, Bozic I. Mathematical model of colorectal cancer initiation. Proc Natl Acad Sci. 2020;117(34):20681\u20138. https:\/\/doi.org\/10.1073\/pnas.2003771117.","journal-title":"Proc Natl Acad Sci"},{"key":"1160_CR5","doi-asserted-by":"publisher","first-page":"goac035","DOI":"10.1093\/gastro\/goac035","volume":"10","author":"S Parmar","year":"2022","unstructured":"Parmar S, Easwaran H. Genetic and epigenetic dependencies in colorectal cancer development. Gastroenterol Rep. 2022;10:goac035. https:\/\/doi.org\/10.1093\/gastro\/goac035.","journal-title":"Gastroenterol Rep"},{"key":"1160_CR6","doi-asserted-by":"publisher","unstructured":"Arvelo F, Sojo F, Cotte C. Biology of colorectal cancer. Ecancermedicalscience. 2015;9. https:\/\/doi.org\/10.3332\/ecancer.2015.520.","DOI":"10.3332\/ecancer.2015.520"},{"issue":"4","key":"1160_CR7","first-page":"507","volume":"7","author":"I Munteanu","year":"2014","unstructured":"Munteanu I, Mastalier B. Genetics of colorectal cancer. J Med Life. 2014;7(4):507.","journal-title":"J Med Life"},{"issue":"20","key":"1160_CR8","doi-asserted-by":"publisher","first-page":"11088","DOI":"10.3390\/ijms222011088","volume":"22","author":"T Pungsrinont","year":"2021","unstructured":"Pungsrinont T, Kallenbach J, Baniahmad A. Role of PI3K-AKT-mTOR pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer. Int J Mol Sci. 2021;22(20):11088. https:\/\/doi.org\/10.3390\/ijms222011088.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1160_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2021.9972","volume":"21","author":"D Miricescu","year":"2021","unstructured":"Miricescu D, Balan DG, Tulin A, Stiru O, Vacaroiu IA, Mihai DA, et al. PI3K\/AKT\/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis. Exp Ther Med. 2021;21(5):1\u20137. https:\/\/doi.org\/10.3892\/etm.2021.9972.","journal-title":"Exp Ther Med"},{"issue":"8","key":"1160_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550\u201362.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1160_CR11","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","volume":"28","author":"KD Courtney","year":"2010","unstructured":"Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1160_CR12","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/ncb2860","volume":"15","author":"P Liu","year":"2013","unstructured":"Liu P, Gan W, Inuzuka H, Lazorchak AS, Gao D, Arojo O, et al. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol. 2013;15(11):1340\u201350.","journal-title":"Nat Cell Biol"},{"key":"1160_CR13","doi-asserted-by":"publisher","first-page":"819128","DOI":"10.3389\/fonc.2022.819128","volume":"12","author":"Y Peng","year":"2022","unstructured":"Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway? Front Oncol. 2022;12:819128.","journal-title":"Front Oncol"},{"issue":"9869","key":"1160_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817\u201324.","journal-title":"Lancet"},{"issue":"9637","key":"1160_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449\u201356.","journal-title":"Lancet"},{"issue":"6","key":"1160_CR16","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer. N Engl J Med. 2012;366(6):520\u20139.","journal-title":"N Engl J Med"},{"issue":"22","key":"1160_CR17","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271\u201381.","journal-title":"N Engl J Med"},{"key":"1160_CR18","doi-asserted-by":"publisher","first-page":"875372","DOI":"10.3389\/fphar.2022.875372","volume":"13","author":"X Wu","year":"2022","unstructured":"Wu X, Xu Y, Liang Q, Yang X, Huang J, Wang J, et al. Recent advances in dual PI3K\/mTOR inhibitors for tumour treatment. Front Pharmacol. 2022;13:875372.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1160_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-020-00396-1","volume":"10","author":"Z Zou","year":"2020","unstructured":"Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 2020;10(1):1\u201311.","journal-title":"Cell Biosci"},{"key":"1160_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3389\/fphar.2020.00206","volume":"11","author":"Y-H Wu","year":"2020","unstructured":"Wu Y-H, Huang Y-F, Chen C-C, Huang C-Y, Chou C-Y. Comparing PI3K\/Akt inhibitors used in ovarian cancer treatment. Front Pharmacol. 2020;11:206.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1160_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-023-01801-2","volume":"22","author":"Y Wu","year":"2023","unstructured":"Wu Y, Song Y, Wang R, Wang T. Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023;22(1):1\u201321.","journal-title":"Mol Cancer"},{"key":"1160_CR22","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00280-019-03922-2","volume":"84","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen W, Wang H, Pan T, Zhang Y, Li C. Upregulation of miR-519 enhances radiosensitivity of esophageal squamous cell carcinoma trough targeting PI3K\/AKT\/mTOR signaling pathway. Cancer Chemother Pharmacol. 2019;84:1209\u201318.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1160_CR23","doi-asserted-by":"publisher","first-page":"117816","DOI":"10.1016\/j.lfs.2020.117816","volume":"255","author":"K Chen","year":"2020","unstructured":"Chen K, Shang Z, Dai A-l, Dai P-l. Novel PI3K\/Akt\/mTOR pathway inhibitors plus radiotherapy: strategy for non-small cell lung cancer with mutant RAS gene. Life Sci. 2020;255:117816.","journal-title":"Life Sci"},{"issue":"12","key":"1160_CR24","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1080\/09553000310001626135","volume":"79","author":"H Machida","year":"2003","unstructured":"Machida H, Matsumoto Y, Shirai M, Kubota N. Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int J Radiat Biol. 2003;79(12):973\u201380. https:\/\/doi.org\/10.1080\/09553000310001626135.","journal-title":"Int J Radiat Biol"},{"issue":"2","key":"1160_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1158\/1535-7163.243.4.2","volume":"4","author":"RW Car\u00f3n","year":"2005","unstructured":"Car\u00f3n RW, Yacoub A, Zhu XY, Mitchell C, Han SI, Sasazuki T, et al. H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. Mol Cancer Ther. 2005;4(2):243\u201355.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1160_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00066-009-1856-4","volume":"185","author":"M Niyazi","year":"2009","unstructured":"Niyazi M, Marini P, Daniel PT, Humphreys R, Jendrossek V, Belka C. Efficacy of a triple treatment with irradiation, agonistic TRAIL receptor antibodies and EGFR blockade. Strahlenther Onkol: Organ der Deutschen R\u00f6ntgengesellschaft [et al]. 2009;185(1):8\u201318.","journal-title":"Strahlenther Onkol: Organ der Deutschen R\u00f6ntgengesellschaft [et al]"},{"issue":"2","key":"1160_CR27","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ijrobp.2009.06.034","volume":"75","author":"SK Sandur","year":"2009","unstructured":"Sandur SK, Deorukhkar A, Pandey MK, Pab\u00f3n AM, Shentu S, Guha S, et al. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys. 2009;75(2):534\u201342.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1160_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00432-008-0475-2","volume":"135","author":"T Yamatodani","year":"2009","unstructured":"Yamatodani T, Ekblad L, Kjell\u00e9n E, Johnsson A, Mineta H, Wennerberg J. Epidermal growth factor receptor status and persistent activation of Akt and p44\/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol. 2009;135(3):395\u2013402.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"1160_CR29","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.ijrobp.2010.02.043","volume":"77","author":"WS Chen","year":"2010","unstructured":"Chen WS, Lee YJ, Yu YC, Hsaio CH, Yen JH, Yu SH, et al. Enhancement of p53-mutant human colorectal cancer cells radiosensitivity by flavonoid fisetin. Int J Radiat Oncol Biol Phys. 2010;77(5):1527\u201335.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1160_CR30","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.bbrc.2010.03.068","volume":"394","author":"SJ Chiu","year":"2010","unstructured":"Chiu SJ, Hsaio CH, Tseng HH, Su YH, Shih WL, Lee JW, Chuah JQ. Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells. Biochem Biophys Res Commun. 2010;394(3):774\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1160_CR31","first-page":"176","volume":"40","author":"SH Sahlberg","year":"2012","unstructured":"Sahlberg SH, Spiegelberg D, Lenartson J, Nygren P, Glimelius B, Stenerl\u00f6w B. The effect of a dimeric affibody molecule (Z EGFR:1907) 2 targeting EGFR in combination with radiation in colon cancer cell lines. Int J Oncol. 2012;40(1):176\u201384.","journal-title":"Int J Oncol"},{"issue":"12","key":"1160_CR32","doi-asserted-by":"publisher","first-page":"e82982","DOI":"10.1371\/journal.pone.0082982","volume":"8","author":"LB Kleiman","year":"2013","unstructured":"Kleiman LB, Krebs AM, Kim SY, Hong TS, Haigis KM. Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers. PLoS ONE. 2013;8(12):e82982.","journal-title":"PLoS ONE"},{"issue":"48","key":"1160_CR33","doi-asserted-by":"publisher","first-page":"9307","DOI":"10.3748\/wjg.v19.i48.9307","volume":"19","author":"Q Xue","year":"2013","unstructured":"Xue Q, Sun K, Deng HJ, Lei ST, Dong JQ, Li GX. Anti-miRNA-221 sensitizes human colorectal carcinoma cells to radiation by upregulating PTEN. World J Gastroenterol. 2013;19(48):9307\u201317.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1160_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00384-013-1754-1","volume":"29","author":"I Palumbo","year":"2014","unstructured":"Palumbo I, Piattoni S, Valentini V, Marini V, Contavalli P, Calzuola M, et al. Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line. Int J Colorectal Dis. 2014;29(1):31\u201341.","journal-title":"Int J Colorectal Dis"},{"key":"1160_CR35","doi-asserted-by":"publisher","unstructured":"Zheng L, Zhang Y, Liu Y, Zhou M, Lu Y, Yuan L, et al. MiR-106b induces cell radioresistance via the PTEN\/PI3K\/AKT pathways and p21 in colorectal cancer. J Transl Med. 2015;13(1). https:\/\/doi.org\/10.1186\/s12967-015-0592-z.","DOI":"10.1186\/s12967-015-0592-z"},{"issue":"2","key":"1160_CR36","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.canlet.2014.12.015","volume":"357","author":"YH Chen","year":"2015","unstructured":"Chen YH, Wei MF, Wang CW, Lee HW, Pan SL, Gao M, et al. Dual phosphoinositide 3-kinase\/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer. Cancer Lett. 2015;357(2):582\u201390. https:\/\/doi.org\/10.1016\/j.canlet.2014.12.015.","journal-title":"Cancer Lett"},{"issue":"3","key":"1160_CR37","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.radonc.2015.06.005","volume":"116","author":"M Poschau","year":"2015","unstructured":"Poschau M, Dickreuter E, Singh-M\u00fcller J, Zscheppang K, Eke I, Liersch T, Cordes N. EGFR and \u03b21-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion. Radiother Oncol. 2015;116(3):510\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2015.06.005.","journal-title":"Radiother Oncol"},{"issue":"5","key":"1160_CR38","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1007\/s13277-015-4399-6","volume":"37","author":"I Pal","year":"2016","unstructured":"Pal I, Dey KK, Chaurasia M, Parida S, Das S, Rajesh Y, et al. Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma. Tumour Biol. 2016;37(5):6389\u2013402. https:\/\/doi.org\/10.1007\/s13277-015-4399-6.","journal-title":"Tumour Biol"},{"issue":"25","key":"1160_CR39","doi-asserted-by":"publisher","first-page":"38191","DOI":"10.18632\/oncotarget.9501","volume":"7","author":"CS Djuzenova","year":"2016","unstructured":"Djuzenova CS, Fiedler V, Katzer A, Michel K, Deckert S, Zimmermann H, et al. Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: the role of drug-irradiation schedule. Oncotarget. 2016;7(25):38191\u2013209. https:\/\/doi.org\/10.18632\/oncotarget.9501.","journal-title":"Oncotarget"},{"key":"1160_CR40","doi-asserted-by":"publisher","unstructured":"Chen YH, Wang CW, Wei MF, Tzeng YS, Lan KH, Cheng AL, Kuo SH. Maintenance BEZ235 treatment prolongs the therapeutic effect of the combination of BEZ235 and radiotherapy for colorectal cancer. Cancers (Basel). 2019;11(8). https:\/\/doi.org\/10.3390\/cancers11081204.","DOI":"10.3390\/cancers11081204"},{"issue":"1","key":"1160_CR41","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3892\/or.2019.7134","volume":"42","author":"H Shiratori","year":"2019","unstructured":"Shiratori H, Kawai K, Hata K, Tanaka T, Nishikawa T, Otani K, et al. The combination of temsirolimus and chloroquine increases radiosensitivity in colorectal cancer cells. Oncol Rep. 2019;42(1):377\u201385. https:\/\/doi.org\/10.3892\/or.2019.7134.","journal-title":"Oncol Rep"},{"issue":"2","key":"1160_CR42","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/0008-5472.Can-19-1161","volume":"80","author":"S Ferrandon","year":"2020","unstructured":"Ferrandon S, DeVecchio J, Duraes L, Chouhan H, Karagkounis G, Davenport J, et al. CoA synthase (COASY) mediates radiation resistance via PI3K signaling in rectal cancer. Can Res. 2020;80(2):334\u201346. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-1161.","journal-title":"Can Res"},{"issue":"7","key":"1160_CR43","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/dcr.0000000000001626","volume":"63","author":"JM Fernandes","year":"2020","unstructured":"Fernandes JM, Jandrey EHF, Koyama FC, Leite KRM, Camargo AA, Costa \u00c9T, et al. Metformin as an alternative radiosensitizing agent to 5-fluorouracil during neoadjuvant treatment for rectal cancer. Dis Colon Rectum. 2020;63(7):918\u201326. https:\/\/doi.org\/10.1097\/dcr.0000000000001626.","journal-title":"Dis Colon Rectum"},{"issue":"8","key":"1160_CR44","doi-asserted-by":"publisher","first-page":"300060520946169","DOI":"10.1177\/0300060520946169","volume":"48","author":"X Li","year":"2020","unstructured":"Li X, Tian R, Liu L, Wang L, He D, Cao K, et al. Andrographolide enhanced radiosensitivity by downregulating glycolysis via the inhibition of the PI3K-Akt-mTOR signaling pathway in HCT116 colorectal cancer cells. J Int Med Res. 2020;48(8):300060520946169. https:\/\/doi.org\/10.1177\/0300060520946169.","journal-title":"J Int Med Res"},{"issue":"6","key":"1160_CR45","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.21037\/jgo-20-210","volume":"11","author":"Y Li","year":"2020","unstructured":"Li Y, Lu K, Zhao B, Zeng XK, Xu S, Ma X, Zhi YQ. Depletion of insulin-like growth factor 1 receptor increases radiosensitivity in colorectal cancer. J Gastrointest Oncol. 2020;11(6):1135\u201345. https:\/\/doi.org\/10.21037\/jgo-20-210.","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"1160_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10010135","volume":"10","author":"JH Park","year":"2021","unstructured":"Park JH, Kim YH, Shim S, Kim A, Jang H, Lee SJ, et al. Radiation-activated pi3k\/akt pathway promotes the induction of cancer stem-like cells via the upregulation of sox2 in colorectal cancer. Cells. 2021;10(1):1\u201314. https:\/\/doi.org\/10.3390\/cells10010135.","journal-title":"Cells"},{"key":"1160_CR47","doi-asserted-by":"publisher","unstructured":"Wanigasooriya K, Barros-Silva JD, Tee L, El-asrag ME, Stodolna A, Pickles OJ, et al. Patient derived organoids confirm that PI3K\/AKT signalling is an escape pathway for radioresistance and a target for therapy in rectal cancer. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.920444.","DOI":"10.3389\/fonc.2022.920444"},{"key":"1160_CR48","doi-asserted-by":"publisher","unstructured":"Li YS, Shen ZY, Chai Z, Zhan YZ, Zhang YW, Liu ZY, et al. Targeting MS4A4A on tumour-associated macrophages restores CD8+T-cell-mediated antitumour immunity. Gut. 2023. https:\/\/doi.org\/10.1136\/gutjnl-2022-329147.","DOI":"10.1136\/gutjnl-2022-329147"},{"key":"1160_CR49","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/btt.S480361","volume":"18","author":"W Zhang","year":"2024","unstructured":"Zhang W, Zhang W, Tang C, Hu Y, Yi K, Xu X, Chen Z. Silencing AREG enhances sensitivity to irradiation by suppressing the PI3K\/AKT signaling pathway in colorectal cancer cells. Biologics. 2024;18:273\u201384. https:\/\/doi.org\/10.2147\/btt.S480361.","journal-title":"Biologics"},{"issue":"12","key":"1160_CR50","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.4251\/wjgo.v16.i12.4716","volume":"16","author":"YB Guo","year":"2024","unstructured":"Guo YB, Wu YM, Lin ZZ. Enhancing the radiosensitivity of colorectal cancer cells by reducing spermine synthase through promoting autophagy and DNA damage. World J Gastrointest Oncol. 2024;16(12):4716\u201327.","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"1160_CR51","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2478\/v10019-012-0030-2","volume":"46","author":"V Velenik","year":"2012","unstructured":"Velenik V, Ocvirk J, Oblak I, Anderluh F. Cetuximab in preoperative treatment of rectal cancer-term outcome of the XERT trial. Radiol Oncol. 2012;46(3):252\u20137.","journal-title":"Radiol Oncol"},{"issue":"2","key":"1160_CR52","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.radonc.2013.03.023","volume":"107","author":"J Buijsen","year":"2013","unstructured":"Buijsen J, Lammering G, Jansen RL, Beets GL, Wals J, Sosef M, et al. Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. Radiother Oncol. 2013;107(2):184\u20138.","journal-title":"Radiother Oncol"},{"issue":"1","key":"1160_CR53","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/annonc\/mdt516","volume":"25","author":"LS Blaszkowsky","year":"2014","unstructured":"Blaszkowsky LS, Ryan DP, Szymonifka J, Borger DR, Zhu AX, Clark JW, et al. Phase I\/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. Ann Oncol. 2014;25(1):121\u20136.","journal-title":"Ann Oncol"},{"issue":"2","key":"1160_CR54","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.radonc.2015.07.039","volume":"116","author":"J Buijsen","year":"2015","unstructured":"Buijsen J, Van Den Bogaard J, Jutten B, Belgers E, Sosef M, Leijtens JWA, et al. A phase I-II study on the combination of rapamycin and short course radiotherapy in rectal cancer. Radiother Oncol. 2015;116(2):214\u201320.","journal-title":"Radiother Oncol"},{"issue":"8","key":"1160_CR55","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1158\/1078-0432.CCR-15-1489","volume":"22","author":"EJ Hill","year":"2016","unstructured":"Hill EJ, Roberts C, Franklin JM, Enescu M, West N, MacGregor TP, et al. Clinical trial of oral nelfinavir before and during radiation therapy for advanced rectal cancer. Clin Cancer Res. 2016;22(8):1922\u201331.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1160_CR56","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3892\/ijo.2014.2601","volume":"45","author":"P Toren","year":"2014","unstructured":"Toren P, Zoubeidi A. Targeting the PI3K\/Akt pathway in prostate cancer: challenges and opportunities. Int J Oncol. 2014;45(5):1793\u2013801.","journal-title":"Int J Oncol"},{"issue":"14","key":"1160_CR57","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.3390\/cancers13143517","volume":"13","author":"H Li","year":"2021","unstructured":"Li H, Prever L, Hirsch E, Gulluni F. Targeting PI3K\/AKT\/mTOR signaling pathway in breast cancer. Cancers. 2021;13(14):3517.","journal-title":"Cancers"},{"issue":"5","key":"1160_CR58","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/cancers12051278","volume":"12","author":"K Wanigasooriya","year":"2020","unstructured":"Wanigasooriya K, Tyler R, Barros-Silva JD, Sinha Y, Ismail T, Beggs AD. Radiosensitising cancer using phosphatidylinositol-3-kinase (PI3K), protein kinase B (AKT) or mammalian target of rapamycin (mTOR) inhibitors. Cancers. 2020;12(5):1278.","journal-title":"Cancers"},{"issue":"6","key":"1160_CR59","doi-asserted-by":"publisher","first-page":"85","DOI":"10.31033\/ijrasb.7.6.14","volume":"7","author":"M Alam","year":"2020","unstructured":"Alam M, Mishra R. Role of PI3K and EGFR in oral cancer progression and drug resistance. Int J Res Appl Sci Biotechnol (IJRASB). 2020;7(6):85\u20139.","journal-title":"Int J Res Appl Sci Biotechnol (IJRASB)"},{"key":"1160_CR60","doi-asserted-by":"publisher","first-page":"110133","DOI":"10.1016\/j.biopha.2020.110133","volume":"128","author":"B Tan","year":"2020","unstructured":"Tan B, Huang Y, Zhang B, Lin N. The effect of ibrutinib on radiosensitivity in pancreatic cancer cells by targeting EGFR\/AKT\/mTOR signaling pathway. Biomed Pharmacother. 2020;128:110133.","journal-title":"Biomed Pharmacother"},{"issue":"01","key":"1160_CR61","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cpt.2022.09.001","volume":"1","author":"H Deng","year":"2023","unstructured":"Deng H, Chen Y, Li P, Hang Q, Zhang P, Jin Y, Chen M. PI3K\/AKT\/mTOR pathway, hypoxia, and glucose metabolism: potential targets to overcome radioresistance in small cell lung cancer. Cancer Pathog Ther. 2023;1(01):56\u201366.","journal-title":"Cancer Pathog Ther"},{"issue":"5","key":"1160_CR62","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41416-019-0677-1","volume":"122","author":"AD Simpson","year":"2020","unstructured":"Simpson AD, Soo YWJ, Rieunier G, Aleksic T, Ansorge O, Jones C, Macaulay VM. Type 1 IGF receptor associates with adverse outcome and cellular radioresistance in paediatric high-grade glioma. Br J Cancer. 2020;122(5):624\u20139.","journal-title":"Br J Cancer"},{"key":"1160_CR63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10549-020-05927-5","volume":"185","author":"L Xue","year":"2021","unstructured":"Xue L, Chen F, Yue F, Camacho L, Kothapalli S, Wei G, et al. Metformin and an insulin\/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer. Breast Cancer Res Treat. 2021;185:73\u201384.","journal-title":"Breast Cancer Res Treat"},{"key":"1160_CR64","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00280-019-03919-x","volume":"84","author":"JM Mehnert","year":"2019","unstructured":"Mehnert JM, Kaveney AD, Malhotra J, Spencer K, Portal D, Goodin S, et al. A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2019;84:899\u2013907.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"1160_CR65","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41575-019-0247-2","volume":"17","author":"AM Buckley","year":"2020","unstructured":"Buckley AM, Lynam-Lennon N, O\u2019Neill H, O\u2019Sullivan J. Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nat Rev Gastroenterol Hepatol. 2020;17(5):298\u2013313.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"1160_CR66","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","volume":"101","author":"A Szwed","year":"2021","unstructured":"Szwed A, Kim E, Jacinto E. Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev. 2021;101(3):1371\u2013426.","journal-title":"Physiol Rev"},{"issue":"16","key":"1160_CR67","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/onc.2016.363","volume":"36","author":"LC Kim","year":"2017","unstructured":"Kim LC, Cook RS, Chen J. mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene. 2017;36(16):2191\u2013201.","journal-title":"Oncogene"},{"issue":"4","key":"1160_CR68","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/acn3.51009","volume":"7","author":"TJ Kaley","year":"2020","unstructured":"Kaley TJ, Panageas KS, Pentsova EI, Mellinghoff IK, Nolan C, Gavrilovic I, et al. Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. Ann Clin Transl Neurol. 2020;7(4):429\u201336.","journal-title":"Ann Clin Transl Neurol"},{"key":"1160_CR69","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00432-014-1594-6","volume":"140","author":"PR Wachsberger","year":"2014","unstructured":"Wachsberger PR, Lawrence YR, Liu Y, Rice B, Feo N, Leiby B, Dicker AP. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. J Cancer Res Clin Oncol. 2014;140:573\u201382.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"1160_CR70","doi-asserted-by":"publisher","first-page":"e2796","DOI":"10.1038\/cddis.2017.119","volume":"8","author":"N Li","year":"2017","unstructured":"Li N, Miao Y, Shan Y, Liu B, Li Y, Zhao L, Jia L. MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K\/Akt pathway in breast cancer. Cell Death Dis. 2017;8(5):e2796\u2013e2796.","journal-title":"Cell Death Dis"},{"issue":"2","key":"1160_CR71","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3892\/ijo.2015.3287","volume":"48","author":"L-X Yan","year":"2016","unstructured":"Yan L-X, Liu Y-H, Xiang J-W, Wu Q-N, Xu L-B, Luo X-L, et al. PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K\/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer. Int J Oncol. 2016;48(2):471\u201384.","journal-title":"Int J Oncol"},{"issue":"4","key":"1160_CR72","doi-asserted-by":"publisher","first-page":"126","DOI":"10.15698\/mic2015.04.196","volume":"2","author":"CC Berti","year":"2015","unstructured":"Berti CC, Dallabona C, Lazzaretti M, Dusi S, Tosi E, Tiranti V, Goffrini P. Modeling human coenzyme A synthase mutation in yeast reveals altered mitochondrial function, lipid content and iron metabolism. Microbial Cell. 2015;2(4):126.","journal-title":"Microbial Cell"},{"issue":"6","key":"1160_CR73","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.3390\/ijms24065951","volume":"24","author":"C Cavestro","year":"2023","unstructured":"Cavestro C, Diodato D, Tiranti V, Di Meo I. Inherited disorders of coenzyme A biosynthesis: models, mechanisms, and treatments. Int J Mol Sci. 2023;24(6):5951.","journal-title":"Int J Mol Sci"},{"key":"1160_CR74","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.addr.2016.02.002","volume":"109","author":"M Krause","year":"2017","unstructured":"Krause M, Dubrovska A, Linge A, Baumann M. Cancer stem cells: radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Adv Drug Deliv Rev. 2017;109:63\u201373.","journal-title":"Adv Drug Deliv Rev"},{"key":"1160_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2509-5","volume":"16","author":"IV Lundberg","year":"2016","unstructured":"Lundberg IV, Edin S, Ekl\u00f6f V, \u00d6berg \u00c5, Palmqvist R, Wikberg ML. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer. BMC Cancer. 2016;16:1\u201311.","journal-title":"BMC Cancer"},{"issue":"1","key":"1160_CR76","doi-asserted-by":"publisher","first-page":"17639","DOI":"10.1038\/s41598-018-36251-0","volume":"8","author":"K Takeda","year":"2018","unstructured":"Takeda K, Mizushima T, Yokoyama Y, Hirose H, Wu X, Qian Y, et al. Sox2 is associated with cancer stem-like properties in colorectal cancer. Sci Rep. 2018;8(1):17639.","journal-title":"Sci Rep"},{"issue":"6230","key":"1160_CR77","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56\u201361.","journal-title":"Science"},{"issue":"6382","key":"1160_CR78","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"4","key":"1160_CR79","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","volume":"182","author":"M Molgora","year":"2020","unstructured":"Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell. 2020;182(4):886\u2013900.e17.","journal-title":"Cell"},{"key":"1160_CR80","doi-asserted-by":"publisher","unstructured":"Ajith A, Mamouni K, Horuzsko DD, Musa A, Dzutsev AK, Fang JR, et al. Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti\u2013PD-1 resistance. J Clin Investig. 2023;133(21). https:\/\/doi.org\/10.1172\/JCI167951.","DOI":"10.1172\/JCI167951"},{"issue":"1","key":"1160_CR81","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1038\/s41598-021-91716-z","volume":"10","author":"K Schwarz","year":"2020","unstructured":"Schwarz K, Dobiasch S, Nguyen L, Schilling D, Combs SE. Modification of radiosensitivity by curcumin in human pancreatic cancer cell lines. Sci Rep. 2020;10(1):3815. https:\/\/doi.org\/10.1038\/s41598-021-91716-z.","journal-title":"Sci Rep"},{"issue":"8","key":"1160_CR82","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1080\/01635581.2019.1681480","volume":"72","author":"K Sak","year":"2020","unstructured":"Sak K. Radiosensitizing potential of curcumin in different cancer models. Nutr Cancer. 2020;72(8):1276\u201389. https:\/\/doi.org\/10.1080\/01635581.2019.1681480.","journal-title":"Nutr Cancer"},{"issue":"1","key":"1160_CR83","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13046-022-02442-x","volume":"41","author":"S Khozooei","year":"2022","unstructured":"Khozooei S, Lettau K, Barletta F, Jost T, Rebholz S, Veerappan S, et al. Fisetin induces DNA double-strand break and interferes with the repair of radiation-induced damage to radiosensitize triple negative breast cancer cells. J Exp Clin Cancer Res. 2022;41(1):256. https:\/\/doi.org\/10.1186\/s13046-022-02442-x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"18","key":"1160_CR84","doi-asserted-by":"publisher","first-page":"8256","DOI":"10.1158\/0008-5472.CAN-05-1220","volume":"65","author":"AK Gupta","year":"2005","unstructured":"Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Can Res. 2005;65(18):8256\u201365. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1220.","journal-title":"Can Res"},{"issue":"10","key":"1160_CR85","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1001\/jamaoncol.2019.2095","volume":"5","author":"R Rengan","year":"2019","unstructured":"Rengan R, Mick R, Pryma DA, Lin LL, Christodouleas J, Plastaras JP, et al. Clinical outcomes of the hiv protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage iiia\/iiib non\u2013small cell lung cancer: a phase 1\/2 trial. JAMA Oncol. 2019;5(10):1464\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2095.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1160_CR86","doi-asserted-by":"publisher","first-page":"e055765","DOI":"10.1136\/bmjopen-2021-055765","volume":"12","author":"S Chopra","year":"2022","unstructured":"Chopra S, Goda JS, Mittal P, Mulani J, Pant S, Pai V, et al. Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial. BMJ Open. 2022;12(4):e055765. https:\/\/doi.org\/10.1136\/bmjopen-2021-055765.","journal-title":"BMJ Open"},{"issue":"6","key":"1160_CR87","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/annonc\/mdv105","volume":"26","author":"E Deutsch","year":"2015","unstructured":"Deutsch E, Le P\u00e9choux C, Faivre L, Rivera S, Tao Y, Pignon J-P, et al. Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. Ann Oncol. 2015;26(6):1223\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdv105.","journal-title":"Ann Oncol"},{"key":"1160_CR88","doi-asserted-by":"publisher","unstructured":"Azria D, Rebillard X, Coux N, Jarlier M, Thuret R, Llacer-Moscardo C, et al. Concurrent treatment with everolimus (RAD001) and hormonoradiotherapy in high-risk locally advanced prostate cancer: results of a phase I trial. Am Soc Clin Oncol. 2013. https:\/\/doi.org\/10.1200\/jco.2013.31.6_suppl.150.","DOI":"10.1200\/jco.2013.31.6_suppl.150"},{"issue":"9","key":"1160_CR89","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/neuonc\/nou328","volume":"17","author":"DJ Ma","year":"2015","unstructured":"Ma DJ, Galanis E, Anderson SK, Schiff D, Kaufmann TJ, Peller PJ, et al. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol. 2015;17(9):1261\u20139. https:\/\/doi.org\/10.1093\/neuonc\/nou328.","journal-title":"Neuro Oncol"},{"issue":"5","key":"1160_CR90","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1200\/JCO.2015.63.1671","volume":"34","author":"SM Magrini","year":"2016","unstructured":"Magrini SM, Buglione M, Corv\u00f2 R, Pirtoli L, Paiar F, Ponticelli P, et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol. 2016;34(5):427\u201335. https:\/\/doi.org\/10.1200\/JCO.2015.63.1671.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01160-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-024-01160-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01160-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T04:22:06Z","timestamp":1737692526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-024-01160-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1160"],"URL":"https:\/\/doi.org\/10.1007\/s12029-024-01160-1","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"11 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"52"}}